Kindred Biosciences Inc Net Income per Employee (KIN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Kindred Biosciences Inc   (NASDAQ: KIN)
 

Kindred Biosciences Inc Net Income per Employee

KIN's Quarterly Results, Trends, Rankings, Statistics
Kindred Biosciences Inc recorded a cumulative net loss of $-42 million during 12 month ending in the second quarter 2021.
The Healthcare sector has seen employees of 330 other companies achieving higher income per employee. While Kindred Biosciences Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 4192.


What is Income per Employee Ratio?






KIN Net Income per Employee (Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,075,615 -225,000 -558,872 -682,872 -762,615
KIN's Total Ranking # 4192 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


KIN Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 331
Healthcare Sector # 755
Overall Market # 4192

Net Income per Employee Statistics
High Average Low
$ -225,000 $ -925,513 $ -1,746,026
(Mar 31 2021)   (Mar 31 2020)







Companies with similar Income per Employee for 12 month ending Jun 30 2021, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2021Number of Employees Jun 30 2021


Date modified: 2026-08-29T17:19:30+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.